Patents by Inventor Quentin N. Myrvik

Quentin N. Myrvik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090324624
    Abstract: A composition and method for the preparation of micro-particles of chitin (a naturally occurring polymer of N-acetyl-D-glucosamine), the characterization of chitin micro-particles as an immune adjuvant and the use of chitin micro-particles to enhance protective immunity against intracellular infectious agents and diseases as well as to inhibit allergic responses and diseases.
    Type: Application
    Filed: May 14, 2008
    Publication date: December 31, 2009
    Applicant: FLORIDA ATLANTIC UNIVERSITY
    Inventors: Yoshimi Shibata, Quentin N. Myrvik
  • Patent number: 5591441
    Abstract: A non-specific host immune cell augmentation composition for enhanced microorganism killing utilizes any phagocytosable, biocompatible particle to prime macrophages for enhanced oxidative response and bacterial killing. Patients can have the benefits of primed macrophages in one to four days, and experiments have demonstrated over a 100-fold increase in oxidative potential within this time period. The oxidative response and killing potential is non-immunospecific, meaning not one organism, not a vaccine, and broadly applicable simultaneously to bacteria and viruses as well as tumor cells. The effects have been demonstrated to have a seven day duration to have a seven day duration indicating non-tissue toxic residual effects and potential for repeated use at monthly intervals.
    Type: Grant
    Filed: February 16, 1994
    Date of Patent: January 7, 1997
    Assignee: Medical Sciences Research Institute
    Inventors: Anthony G. Gristina, Quentin N. Myrvik
  • Patent number: 5530102
    Abstract: Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue at times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, CNS, Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp., etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to viral or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: June 25, 1996
    Inventors: Anthony G. Gristina, Quentin N. Myrvik
  • Patent number: 5505945
    Abstract: Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, Coagulase Negative Staphylococci Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp., etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to viral or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release.
    Type: Grant
    Filed: August 25, 1994
    Date of Patent: April 9, 1996
    Assignee: Medical Sciences Research Institute
    Inventors: Anthony G. Gristina, Quentin N. Myrvik
  • Patent number: 5292513
    Abstract: A non-specific host defense cell augmentation technique for enhanced microorganism killing utilizes any phagocytosable, biocompatible particle to prime macrophages for enhanced oxidative response and bacterial killing. Patients can have the benefits of primed macrophages in one to four days, and experiments have demonstrated over a 100-fold increase in oxidative potential within this time period. The oxidative response and killing potential is non-immunospecific, meaning not one organism, not a vaccine, and broadly applicable simultaneously to bacteria and viruses as well as tumor cells. The effects have been demonstrated to have a seven day duration indicating non-tissue toxic residual effects and potential for repeated use at monthly intervals.
    Type: Grant
    Filed: May 18, 1992
    Date of Patent: March 8, 1994
    Assignee: Anthony G. Gristina
    Inventors: Anthony G. Gristina, Quentin N. Myrvik